首页> 美国卫生研究院文献>Annals of Hepato-Biliary-Pancreatic Surgery >Management of very late peritoneal metastasis of hepatocellular carcinoma 10 years after liver transplantation: Lessons from two cases
【2h】

Management of very late peritoneal metastasis of hepatocellular carcinoma 10 years after liver transplantation: Lessons from two cases

机译:肝移植后10年肝细胞癌极晚期腹膜转移的处理:两个案例的经验教训

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Recurrence of hepatocellular carcinoma (HCC) 10 years after liver transplantation (LT) is very rare. Here, we present two cases of peritoneal metastasis of HCC that occurred 10 and 12 years after LT. A 77-year-old male who had undergone deceased-donor LT 10 years earlier showed slow progressive elevation of tumor marker levels over 6 months. Close observation with frequent imaging studies and monthly tumor marker analyses revealed a solitary peritoneal seeding mass. Imaging studies revealed that the mass was highly likely to be metastatic HCC. After excision of the mass, all tumor markers returned to the normal range. Over past 10 months, the patient has received everolimus monotherapy and half-dose sorafenib, and has shown no evidence of HCC recurrence. In the second case, marginally elevated tumor marker levels were detected in a 65-year-old male who had undergone living-donor LT 12 years earlier. After observation for 3 months, follow-up studies revealed a peritoneal seeding mass. Thorough imaging studies revealed that the mass was highly likely to be metastatic HCC. Two mass lesions were excised, and the patient was administered low-dose calcineruin inhibitor, sirolimus, and full-dose sorafenib. Subsequently, the tumor marker levels increased again and growth of new peritoneal seeding nodules was observed; therefore, sorafenib was stopped after 2 years of administration. During 6 years since HCC recurrence diagnosis, the patient has experienced slowly growing tumors, but has been doing well. For very late peritoneal metastasis of HCC, the therapeutic modalities include surgical resection if possible, everolimus monotherapy, and long-term use of sorafenib.
机译:肝移植(LT)后10年肝细胞癌(HCC)的复发非常罕见。在这里,我们介绍了发生在LT后10年和12年的2例HCC腹膜转移病例。一位10年前接受过死者LT治疗的77岁男性在6个月内显示出缓慢的肿瘤标志物水平逐步升高。通过频繁的影像学研究和每月的肿瘤标志物分析进行密切观察,发现单个的腹膜播种量。影像学检查显示该肿块极有可能是转移性肝癌。切除肿块后,所有肿瘤标志物均恢复正常范围。在过去的10个月中,该患者接受了依维莫司单药和半剂量索拉非尼的治疗,并且未显示出HCC复发的证据。在第二种情况下,在12岁之前接受活体供体LT的65岁男性中检测到肿瘤标志物水平略有升高。观察3个月后,后续研究发现了腹膜播种物。全面的影像学研究表明,肿块极有可能是转移性肝癌。切下两个肿块,向患者服用低剂量钙调神经磷酸酶抑制剂,西罗莫司和全剂量索拉非尼。随后,肿瘤标志物水平再次增加,并观察到新的腹膜播种结节的生长。因此,索拉非尼给药2年后停止使用。自HCC复发诊断以来的6年中,该患者经历了缓慢生长的肿瘤,但情况一直良好。对于晚期肝癌腹膜转移,治疗方法包括手术切除(如果可能),依维莫司单药治疗和长期使用索拉非尼。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号